View
225
Download
4
Category
Tags:
Preview:
Citation preview
Intuitive Surgical
$ by Darrin Scilley
1/2/2
008
1/20/2
008
2/7/2
008
2/25/2
008
3/14/2
008
4/1/2
008
4/19/2
008
5/7/2
008
5/25/2
008
6/12/2
008
6/30/2
008
7/18/2
008
8/5/2
008
8/23/2
008
9/10/2
008
9/28/2
008
10/16/2
008
11/3/2
008
11/21/2
008
12/9/2
008
12/27/2
008
1/14/2
009
2/1/2
009
2/19/2
009
3/9/2
009
3/27/2
009
4/14/2
009
5/2/2
009
5/20/2
009
6/7/2
009
6/25/2
009
7/13/2
009
7/31/2
009
8/18/2
009
9/5/2
009
9/23/2
009
10/11/2
009
10/29/2
009
11/16/2
009
12/4/2
009
12/22/2
009
1/9/2
010
1/27/2
0100
200
400
600
800
1000
1200
1400
1600
0
50
100
150
200
250
300
350
400Historical Prices
S&P 500 Healthcare ISRG (L)
Purchase
2/2/2
009
2/11/2
009
2/20/2
009
3/1/2
009
3/10/2
009
3/19/2
009
3/28/2
009
4/6/2
009
4/15/2
009
4/24/2
009
5/3/2
009
5/12/2
009
5/21/2
009
5/30/2
009
6/8/2
009
6/17/2
009
6/26/2
009
7/5/2
009
7/14/2
009
7/23/2
009
8/1/2
009
8/10/2
009
8/19/2
009
8/28/2
009
9/6/2
009
9/15/2
009
9/24/2
009
10/3/2
009
10/12/2
009
10/21/2
009
10/30/2
009
11/8/2
009
11/17/2
009
11/26/2
009
12/5/2
009
12/14/2
009
12/23/2
009
1/1/2
010
1/10/2
010
1/19/2
010
1/28/2
010
2/6/2
0100
50
100
150
200
250
300
350
Total Return Percentage
ISRG S&P 500 Healthcare
Sector Components
• Managed Care• Facilities• Biotechnology• Pharmaceuticals• Healthcare Products and Supplies
Sector Analysis• Facilities eliminated
– Decreasing revenues + Increasing costs• Pharmaceuticals eliminated
– Slowing growth• Biotech possible
– High growth, but FDA/legal hurdles• Managed Care possible
– Rising GDP = rising costs– Possible Medicare/Medicaid penetration
• Medical Products and Supplies likely– High growth, recession resistant
Selection Process
• Debt Maturity
• Leverage
• Multiples
• Historical Growth
P/E2008Growth
Intuitive Surgical 21.38 45.83%
Bard 21.01 12.36%
St. Jude Medical 33.68 15.45%
Medtronic 16.58 9.89%
Stryker Corp 15.17 11.97%
Baxter International 18.58 9.59%
Varian Medical Systems 17.19 17.89%
Becton, Dickinson and Co. 15.92 12.52%
Multiples Forward Mutliples
P/EBITDA EV/EBITDA 1 yr CAGR 2 yr CAGR 5 yr CAGR2009EV/EBITDA
2010EV/EBITDA
2013EV/EBITDA
Intuitive Surgical (ISRG) 12.04 9.35 15.00% 25.00% 21.00% 8.13 6.51 3.61
Johnson and Johnson (JNJ) 7.45 7.40 -1.10% 8.70% 8.25% 7.48 6.89 4.98
St. Jude Medical (STJ) 14.44 14.55 9.10% 13.50% 13.10% 13.34 11.75 7.86
Medtronic (MDT) 7.16 7.68 12.70% 9.60% 11.35% 6.82 6.22 4.49
Stryker (SYK) 6.81 5.71 9.50% 12.80% 14.20% 5.21 4.62 2.94
Baxter (BAX) 9.94 10.46 10.70% 13.40% 12.48% 11.58 8.33 5.81
Pfizer (PFE) 6.31 5.10 -16.00% 12.00% 0.75% 4.28 5.42 4.91
Expected Return
EarningsPrice Per Share
Dividend/Share Repurchase
Forward Shares P/E
End P/E
Yearly Decay
ForwardP/E
2009 CAGR Expected Return
Intuitive Surgical (ISRG) 204,315 $103.03 0.00 300,000 36,338 19.79 15.08 -0.94 18.85 15.00% 18.30%
Johnson and Johnson (JNJ) 12,949,000 $50.64 1.80 2,000,000 2,730,506 10.83 15.08 0.85 11.68 -1.10% 11.74%
St. Jude Medical (STJ) 353,020 $36.67 0.00 0 346,150 35.96 15.08 -4.18 31.78 9.10% -3.57%
Medtronic (MDT) 2,169,000 $28.58 0.53 0 1,102,000 14.76 15.08 0.06 14.82 12.70% 16.90%
Stryker (SYK) 1,147,000 $33.81 0.50 600,000 378,784 11.69 15.08 0.68 12.37 9.50% 22.76%
Baxter (BAX) 2,014,000 $51.16 1.25 1,200,000 590,394 15.59 15.08 -0.10 15.49 10.70% 16.78%
Pfizer (PFE) 8,026,000 $14.54 1.28 5,000,000 6,406,121 12.23 15.08 0.57 12.80 -16.00% 1.44%
Who is ISRG?
Who is ISRG?
• 205,000 procedures in 2009– Up 51% from 2008
• Revenue $1,050M, up 20% from 2008• Operating Profit $377M, up 21% from 2008• 71% Gross Margin, 36% Operating Margin• $1,171M Cash
– 25% Mkt Cap 9% Mkt Cap
ISRG’s Fit in Healthcare• Healthcare Keys to Success
– New/existing product innovation– International expansion– Form strategic alliances– Lower managed care costs– Improve patients’ lives
• How ISRG fits– Pioneers of RAS/MIS– See international map– Numerous acquisitions/partnerships– ROI 20%-30%+– 3-4 year payback period– Inpatient Outpatient conversion– Decreased length of stay– Decreased nursing/staffing– Decreased blood loss/complications– Improved patient satisfaction
Risk Factors
• Competition• Economic/political environment• Continued market acceptance• Malfunctions• Single Source Suppliers
Valuation Key 1: Revenue
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 20230.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
45.00%
ProcedureSystemOverall
PROCEDURE
SYSTEM
Procedures
Adoption Curve
International Adoption
Revenue Split
Key Driver 2: Market Share
Scenario Analysis
Recommended